
Traws Pharma (TRAW) Stock Forecast & Price Target
Traws Pharma (TRAW) Analyst Ratings
Bulls say
Traws Pharma is facing a critical time as the company's Phase 2a challenge study for Tivoxavir marboxil has been halted due to MHRA setback, and with only $5.0M of cash, the company is relying on anticipated ATM proceeds to fund operations into 1Q27. Despite this challenge, the company's recent financing of up to $60M provides a cash runway to 1Q27 and allows for potential warrant exercises that could bring additional funding. The success of their bridging study in evaluating the compressed tablet formulation and MHRA approval will be crucial for the company's future growth and investors' confidence.
Bears say
Traws Pharma is a clinical-stage biopharmaceutical company with limited value in its early-stage Ebola and hantavirus program, due to uncertainty surrounding the size and durability of any commercial opportunity. With a high WACC of 19.0% and an 8.0x exit multiple, the potential for upside risks is heavily mitigated by financing, clinical trial, regulatory, delisting, and bankruptcy risks, despite potential pipeline success for COVID, hantavirus, or Ebola. Its net proceeds from sale and purchase of securities remain immaterial in terms of improving its overall outlook.
This aggregate rating is based on analysts' research of Traws Pharma and is not a guaranteed prediction by Public.com or investment advice.
Traws Pharma (TRAW) Analyst Forecast & Price Prediction
Start investing in Traws Pharma (TRAW)
Order type
Buy in
Order amount
Est. shares
0 shares